Interferon-α-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves’ disease

Autoimmune thyroid disease is a common side-effect of interferon-α (IFN-α) treatment of viral hepatitis C. We have described three patients with hepatitis C for whom IFN-α and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse...

Full description

Saved in:
Bibliographic Details
Published in:European journal of endocrinology 2006-03, Vol.154 (3), p.367-372
Main Authors: Bohbot, Nathalie Lévy, Young, Jacques, Orgiazzi, Jacques, Buffet, Catherine, François, Maud, Bernard-Chabert, Brigitte, Lukas-Croisier, Céline, Delemer, Brigitte
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Clinical Studies
Endocrinopathies
Fundamental and applied biological sciences. Psychology
Graves Disease - chemically induced
Graves Disease - diagnostic imaging
Graves Disease - pathology
Hepatitis C - complications
Hepatitis C - drug therapy
Humans
Hyperthyroidism - chemically induced
Hyperthyroidism - diagnostic imaging
Hyperthyroidism - pathology
Interferon Type I - adverse effects
Interferon Type I - therapeutic use
Male
Medical sciences
Non tumoral diseases. Target tissue resistance. Benign neoplasms
Radionuclide Imaging
Recombinant Proteins
Thyroid Function Tests
Thyroid Hormones - blood
Thyroid. Thyroid axis (diseases)
Thyroiditis - chemically induced
Thyroiditis - diagnostic imaging
Thyroiditis - pathology
Vertebrates: endocrinology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autoimmune thyroid disease is a common side-effect of interferon-α (IFN-α) treatment of viral hepatitis C. We have described three patients with hepatitis C for whom IFN-α and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves’ disease. These three men had no known history of familial or personal thyroid disease. Destructive thyrotoxicosis appeared 4–6 months after starting IFN-α, followed by Graves’ hyperthyroidism within 8 to11 months. The thyrotropin (TSH) level was normal before IFN-α was started. The diagnosis of destructive thyroiditis was confirmed by anti-TSH receptor antibody (TSHRAb) negativity and the absence of radionuclide (123I or 99Tc) uptake on thyroid scintiscans. Eight to eleven months after starting treatment, TSHRAb positivity and intense scintigraphic uptake confirmed the appearance of Graves’ disease. IFN-α was continued in only one patient. Hence, hyperthyroidism induced by IFN-α could correspond to the first phase of silent thyroiditis, to Graves’ disease or to the succession of both. Rigorous diagnostic procedures with repeated scintiscans and TSHRAb titering are necessary to avoid a false diagnosis and inappropriate therapy.
ISSN:0804-4643
1479-683X
DOI:10.1530/eje.1.02104